Telesis Bio

Telesis Bio Capital Intensity

The Capital Intensity Ratio of Telesis Bio (TBIO) as of Oct 29, 2026 is 255.96 %. In the previous year, Capital Intensity Ratio was 296.56 % — a change of -13.69% (lower).

Capital Intensity

255.96 %

YoY

-13.69%

Last updated:

Capital Intensity Ratio of Telesis Bio is 2023 255.96 % . Capital Intensity Ratio of Telesis Bio was 2022 296.56 % . It decreases by -13.69% lower compared to the previous year.

The Telesis Bio Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
20,257.11 USD
Jan 1, 2019
806.68 USD
Jan 1, 2020
408.50 USD
Jan 1, 2021
1,052.77 USD
Jan 1, 2022
296.56 USD
Jan 1, 2023
255.96 USD
The Telesis Bio Capital Intensity history
YEARCapital IntensityYoY
255.96 %-13.69%
296.56 %-71.83%
1,052.77 %+157.71%
408.50 %-49.36%
806.68 %-96.02%
20,257.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telesis Bio Stock analysis

What does Telesis Bio do? Codex DNA, Inc. develops genomic tools for biomedical and industrial applications, focusing on synthetic biology solutions to overcome bottlenecks in DNA and mRNA production. Its BioXp systems, including the BioXp 3250, serve as end-to-end automated workstations, while BioXp kits generate synthetic DNA and mRNA. The company offers 14 SARS-CoV-2 full-length genomes, RNA controls, and Vmax X2 cells as part of its product portfolio. BioXp systems are placed globally with approximately 200 units deployed. The firm targets researchers and biotech companies needing scalable DNA and mRNA synthesis, leveraging its automated workflow solutions. Products like BioXp kits and benchtop reagents complement the core systems, addressing limitations in current solutions. The company has launched eight BioXp kits and three benchtop reagent kits, supporting applications across biomedical and industrial sectors. Revenue streams come from selling BioXp systems, kits, and reagents directly to research institutions and biotechnology firms. The BioXp 3250 system, BioXp kits, and benchtop reagent kits are key products driving sales. Vmax X2 cells and SARS-CoV-2 related products also contribute to the company's revenue. Global deployment of 200 BioXp systems indicates strong market adoption among customers in the synthetic biology space. Telesis Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telesis Bio stock

Capital Intensity Ratio of Telesis Bio is 255.96 % in 2023.

Capital Intensity Ratio of Telesis Bio changed from 296.56 % to 255.96 %, representing a -13.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Telesis Bio since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Telesis Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Telesis Bio

All Key Metrics — Telesis Bio